🔎 Trials Near Me

Home › Triple-Negative Breast Cancer › California › Mountain View

Triple-Negative Breast Cancer clinical trials in Mountain View, CA

8 studies for Triple-Negative Breast Cancer are looking for participants at sites in and around Mountain View (within about 30 miles). Open a study to see who can join and how to contact the study team.

Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

RecruitingObservational study
  • Stanford University, Palo Alto · 5 mi away
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT04981119

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

RecruitingPhase 3
  • El Camino Hospital Cancer Center ( Site 0096), Mountain View
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT06966700

Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer

RecruitingPhase 2
  • Stanford University, Stanford · 5 mi away
Ages 18 and older · All sexes · Updated Aug 12, 2026 · NCT04768426

Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

RecruitingPhase 1
  • Stanford University Medical Center, Palo Alto · 5 mi away
Ages 18 to 100 · All sexes · Updated Jul 29, 2026 · NCT06562192

A Study of LY4175408 in Participants With Advanced Cancer

RecruitingPhase 1
  • Stanford Medicine Cancer Center, Stanford · 5 mi away
Ages 18 and older · All sexes · Updated Jun 23, 2026 · NCT07046923

Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies

RecruitingPhase 1
  • Stanford University, Stanford · 5 mi away
Ages 18 and older · All sexes · Updated Feb 8, 2024 · NCT04282044

Triple-Negative Breast Cancer trials in other cities

Other studies in Mountain View

From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.